Lexaria Celebrates its 70th Patent Award
Lexaria Bioscience announced its 70th granted patent, covering new international awards across its DehydraTECH drug delivery platform. Four recent grants were detailed: two US patents in diabetes families (including coverage of GLP-1 molecules such as semaglutide and tirzepatide), a Canadian patent for CBD in hypertension, and a European patent for CBD in epilepsy.
Key figures
- Recent grants
- ["US Patent 12,691,163 (July 28, 2026) - GLP-1 molecules, Family #27 Diabetes","US Patent 12,758,566 (October 13, 2026) - CBD, Family #26 Diabetes","Canadian Patent 3,199,547 (October 20, 2026) - CBD, Family #21 Hypertension","European Patent 4522159 (October 21, 2026) - CBD, Family #24 Epilepsy"]
- Patents granted
- 70
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.